The global animal model market is expected to witness significant growth, with a projected revenue of approximately USD 1,943.3 million in 2024. Expanding at a compound annual growth rate (CAGR) of 6% over the next decade, the market is forecast to reach nearly USD 3,476.8 million by the end of the forecast period in 2034. This growth is driven by the increasing demand for animal models in medical research, drug development, and toxicity testing.
Animal models, due to their shorter life cycles, high genotype similarity to humans, and ease of use in laboratory settings, are indispensable tools in biomedical research. They provide valuable insights into disease mechanisms, therapeutic interventions, and safety testing for new treatments. This, combined with the growing need for more advanced and accurate testing methods, is fueling the market’s expansion.
The demand for animal models is particularly strong in fields such as oncology, immunology, and genetic research, where reliable and reproducible data is essential. Furthermore, the rising focus on personalized medicine and biotechnology innovations is expected to further accelerate market growth, as animal models remain critical for understanding complex biological processes.
North America currently holds a dominant position in the animal model market, attributed to the region’s robust healthcare research infrastructure and significant investments in pharmaceutical and biotechnological advancements. Meanwhile, the Asia-Pacific region is projected to witness rapid growth due to increasing research initiatives, improved laboratory facilities, and a growing focus on healthcare innovation.
Animal Model Market Trends and Analysis
- Traditionally, animal models, like humanized mice, are used prominently in biomedical research that helps develop new treatment methods for various diseases. But, now, demand for different species of animals has increased in the healthcare sector as it offers a better understanding of other diseases, along with the efficacy of drugs with regard to many diseases.
- The development of genetically modified animals for preclinical models that are more predictive in being effective is an arduous and time-consuming process. However, recent progress being made in animal studies and researchers applying new experimental approaches to elucidate the biology of specific diseases has curbed this challenge.
Key Takeaways:
- The global animal model market is expected to grow from USD 1,943.3 million in 2024 to USD 3,476.8 million by 2034, at a CAGR of 6%.
- The demand for animal models is fueled by their critical role in medical research, drug development, and disease understanding.
- Oncology, immunology, and genetic research are major fields driving the adoption of animal models.
- North America leads the market, while Asia-Pacific is set to experience significant growth due to increasing research initiatives and healthcare investments.
Growth Drivers
- The increasing incidence of diseases requiring extensive research, such as cancer and neurological disorders, is a significant factor driving the demand for animal models.
- The benefits of using animals in research—such as shorter life cycles, high genotype resemblance to humans, and ease of laboratory testing—further enhance their utility in biomedical research.
Market Segmentation
- The market is segmented based on:
- Animal Type: Mice, rats, guinea pigs, rabbits, and others.
- Application: Cancer research, immunological disease studies, infectious disease research, and more.
- End-Use: Pharmaceutical and biotechnology companies, academic research institutions, and contract research organizations (CROs).
Regional Insights
- North America is expected to maintain a dominant share of the market due to advanced research facilities and high investment in biomedical research.
- The Asia-Pacific region is projected to experience the fastest growth rate driven by increasing government support for research initiatives and rising healthcare demands.
Competitive Landscape
Key animal model system providers are focusing on strategic acquisitions, mergers, collaborations, and partnerships to grow their client base and boost their industrial position. Recent investments by leading companies have created prospects for the market to expand globally.
The market is now highly influenced by technological interventions in software modeling for time and cost efficiency, along with the growing ethical concerns in reducing the number of live animals used for research. Recent key developments in the market include the development of a novel monkey research model using CRISPR technology.
Recent Developments in the Global Animal Model Market
In January 2020, Horizon Discovery Group plc. confirmed a partnership and license deal with Mammoth Biosciences to gain access to Mammoth’s unique CRISPR technology. The partnership is expected to make it easier for Horizon to provide a new generation of genetically altered CHO cells to manufacture biotherapeutics such as therapeutic antibodies.
In March 2022, Charles River Laboratories and Hera Biolabs inked a contract for the breeding, marketing, and sales of SRG rats to the world’s preclinical research community. Through this deliberate partnership, Hera BioLabs is aiming to expand the geographic reach of its highly immunodeficient rat model.
Key Players Profiled in the Animal Model Market Report
- Charles River Laboratories International, Inc.
- Horizon Discovery Group plc.
- The Jackson Laboratory
- Taconic Biosciences, Inc.
- Genoway SA
- Eurofins Scientific SE
- Crown Bioscience, Inc.
- Envigo CRS SA
- Transposagen Biopharmaceuticals, Inc.
A Full Report Overview
Key Segments Covered by Animal Model Industry Survey Report
By Species Type:
- Rats
- Mice
- Guinea Pigs
- Rabbits
- Monkeys
- Dogs
- Pigs
- Cats
- Other Species
By Application:
- Basic and Applied Research
- Drug Discovery and Development
- Other Applications
By End User:
- Academic & Research Institutions
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Other End Users
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia and Pacific
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
